Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(13%)
Results Posted
83%(5 trials)

Phase Distribution

Ph phase_2
1
13%
Ph not_applicable
1
13%
Ph phase_4
1
13%
Ph phase_3
3
38%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Other(1)

Detailed Status

Completed6
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 33 (42.9%)
Phase 41 (14.3%)
N/A1 (14.3%)

Trials by Status

completed675%
recruiting113%
unknown113%

Recent Activity

1 active trials
Showing 5 of 8
recruitingnot_applicable

The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY

NCT06823596
completedphase_4

Efavirenz (EFV) Intensification

NCT07193875
completedphase_2

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

NCT00964171
completedphase_1

Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.

NCT01878890
unknownphase_3

Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients

NCT04513379
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06823596Not Applicable

The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY

Recruiting
NCT07193875Phase 4

Efavirenz (EFV) Intensification

Completed
NCT00964171Phase 2

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Completed
NCT01878890Phase 1

Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.

Completed
NCT04513379Phase 3

Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients

Unknown
NCT01011413Phase 3

Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.

Completed
NCT01410058

Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction

Completed
NCT00727597Phase 3

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8